Yankees Score with ...
Health Care: Drugs
Cleveland BioLabs Inc. (CBLI: NASDAQ)
$1.66 0.02 | 1.22%
05/24/13 - 03:59 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 3.57M | 8.79M | 15.33M | 14.35M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 3.57M | 8.79M | 15.33M | 14.35M |
| Selling, General, and Administrative Expenses | 11.12M | 11.11M | 9.93M | 6.40M |
| Research & Development | 22.50M | 22.79M | 16.14M | 14.33M |
| Operating Income before D & A (EBITDA) | -30.05M | -25.11M | -10.74M | -6.38M |
| Depreciation & Amortization | 479.60K | 525.51K | 407.29K | 362.14K |
| Interest Income | 0.00 | 183.66K | 99.11K | 21.69K |
| Other Income - Net | 7.70M | 19.69M | -16.03M | -6.46M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -22.82M | -5.76M | -27.08M | -13.19M |
| Interest Expense | 70.02K | 0.00 | 0.00 | 1.96K |
| Pre-Tax Income | -22.89M | -5.76M | -27.08M | -13.19M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | -4.18M | -1.22M | -305.81K | 0.00 |
| Net Income From Continuing Operations | -22.41M | -5.23M | -26.67M | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -22.41M | -5.23M | -26.67M | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -18.23M | -4.01M | -26.37M | -12.83M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-22.41M | -5.23M | -26.67M | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -22.41M | -5.23M | -26.67M | -615.35K |
| Basic EPS from Continuing Ops. | -0.49 | -0.12 | -1.01 | -0.82 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.49 | -0.12 | -1.01 | -0.82 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.49 | -0.12 | -1.01 | -0.82 |
| Basic Normalized Net Income/Share | -0.49 | -0.12 | -1.01 | n.a. |
| EPS fr Continuing Ops. | -0.49 | -0.12 | -1.01 | -0.82 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.49 | -0.12 | -1.01 | -0.82 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.49 | -0.12 | -1.01 | -0.82 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.49 | -0.12 | -1.01 | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CBLI
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Health Care Stocks With U...
- Contributor10 Surging Stocks Most at R...
- UserNEW HOME savings
- UserDan128
- UserJustchattin Portfolio 1
- UserSPQR
Latest CBLI Headlines from TheStreet
- Cleveland BioLabs And Incuron Announce US And European Patent Allowances For Curaxins 05.14.13 | 07:05 am
- CORRECTION -- Cleveland BioLabs Reports First Quarter 2013 Financial Results And Development Progress 05.09.13 | 09:05 am
- Cleveland BioLabs Reports First Quarter 2013 Financial Results And Development Progress 05.09.13 | 07:05 am
- Cleveland BioLabs Announces Appointment Of Shareholder Representative To Board 05.08.13 | 07:05 am
- Cleveland BioLabs, Roswell Park Announce Publication Of Studies Defining Role Of Liver In Activity Of Entolimod (CBLB502) 05.01.13 | 07:05 am
- Cleveland BioLabs To Report First Quarter 2013 Financial Results And Provide Operational Update On May 9 04.30.13 | 07:04 am
- Cleveland BioLabs Announces Changes To Board Of Directors 04.23.13 | 07:04 am
- Cleveland BioLabs Strengthens Clinical Development Team 04.08.13 | 10:04 am
- Cleveland BioLabs And Incuron Announce Notice Of Allowance From FDA To Commence Clinical Testing With CBL0137 04.02.13 | 07:04 am
- 5 Stocks Under $10 Triggering Breakouts 03.21.13 | 01:03 pm
Press Releases for CBLI
- Cleveland BioLabs To Present At Second Annual Marcum LLP Microcap Conference - PR Newswire 05.22.13 | 08:05 am
- Mintz Levin Represents Cleveland Biolabs, Inc. In $8.4 Million Direct Offering - Business Wire 01.04.11 | 09:01 am
Partner Headlines for CBLI
- Acute Radiation Syndrome, Are We Prepared And Who Is Best Preparing Us? - Seeking Alpha 02.27.13 | 09:02 am
- Five Micro Cap Stocks With Recent Insider Buys - Benzinga 07.06.12 | 05:07 pm
- Morning Market Losers - Benzinga 06.05.12 | 09:06 am
- Morning Market Movers - Benzinga 06.04.12 | 09:06 am
- Ultimate Market Recap: Medtox Makes Good, BofA Holds Out on Shareholders - Wall St. Cheat Sheet 06.04.12 | 07:06 am
- 3 Stocks Illuminating Green on a Red Trading Day - Wall St. Cheat Sheet 06.04.12 | 02:06 am
- Will the Next Apple or Google Be Found Among These Micro Caps? - Seeking Alpha 08.18.11 | 09:08 am
- Rodman & Renshaw Lower Cleveland BioLabs PT to $8 - Benzinga 06.27.11 | 04:06 pm
- Zacks #5 Rank Additions for Monday - Tale of the Tape - Zacks 06.20.11 | 09:06 am
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
